Bone morphogenetic proteins (BMPs) that are classified under transforming growth factor beta superfamily are multifactorial growth factors. These are naturally occurring proteins found in the human body, involved in numerous cellular responses. BMPs were first isolated in 1965 by scientist Marshall Urist for the ability to induce the formation of bone and cartilage. To date over 15 BMPs have been isolated and cloned. However, only BMP-2 and BMP-7 are considered to show the greatest amount of osteoinductive potential. Both the types of BMPs share similar kind of cell receptors (Type 1 and Type 2 BMP receptor) that help in regulating bone growth. Thus, for clinical use, BMPs are produced through recombinant DNA technology namely rhBMP-2 and rhBMP-7. These BMPs have been approved by the FDA for use in orthopedic applications such as spinal fusions, oral surgery, and tibia non-unions. These proteins posses the ability to induce patients own cells for bone formation. In addition, BMPs have proved to be beneficial for patients undergoing spinal fusion surgery by eliminating the need for bone harvesting from the pelvis region. This innovative research approach also reduces the amount of pain, dependence on spinal rods or screws, and augments the rate of spinal fusion. Although, BMPs have proved to be a noteworthy bone graft substitute in spinal fusion, a variety of complications are associated with its off-label usage. Uncontrolled bone formation, bone overgrowth, male sterility, leg pain, back pain, respiratory complication, and inflammation are some of the side effects associated with the implant of BMPs. Thus, the market for BMPs has been restricted by biocompatibility issues, high cost, strict regulations, and presence of numerous bone graft substitutes.
The global bone morphogenetic proteins market is studied based on the types of recombinant BMPs, applications, and geography. Based on recombinant BMP types, the market has been further segmented into two major segments namely, rhBMP-2 and liquid rhBMP-7. Among the type segments, the rhBMP-2 segment accounted for the largest share (in terms of revenue) of the market in 2013. rhBMP-2 has been widely accepted by physicians and surgeons across the globe due to their effectiveness in treating lower back spinal fusions. rhBMP-7 on the other hand is expected to completely diminish from the market in the future due to withdrawal of OP-1/Opgenra from the market since August 2014. In terms of application, spinal fusion currently accounts for the largest share of the market, followed by trauma. However, the reconstructive segment is likely to grow at a low CAGR during the forecast period from 2014 to 2022. The reason for sluggish growth is limited usage of BMP products for reconstructive surgery and presence of numerous well-established alternative bone graft substitutes.
In terms of regional distribution, North America currently accounts for the largest share of the bone morphogenetic proteins market, followed by Europe. Furthermore, North America, with a market share of over 70%, is expected to dominate the industry during the forecast period. This leadership would be witnessed due to high awareness about BMP products, availability of premium priced recombinant BMP products, and soaring number of spinal fusion procedures. Furthermore, highest growth of this industry is expected to emerge in Asia Pacific during the forecast period. The global bone morphogenetic proteins market is characterized by three players namely Medtronic plc, Olympus Biotech, and Cellumed.
Bone morphogenetic proteins (BMP) are naturally occurring proteins found in the human body. Identified in 1965 by Marshall Urist, bone morphogenetic proteins are among the most potent growth factors that induce mesenchymal stem cells to differentiate into osteoblast cells. Twenty different types of BMPs have been discovered to date; only BMP 2, 7 and 9 have osteoinductive property and have been proven to play a significant role in bone formation. However, of these, only BMP-2 and BMP-7 are commercially available. These proteins trigger intracellular signal pathways by binding to the receptor of the mesenchymal stem cells resulting in transformation of stem cells into tissue specific progenitor cells. These cells are involved in the synthesis of musculoskeletal tissue formation, extracellular growth and matrix.
The bone morphogenetic proteins market report studies the current scenario as well as future market potential for bone morphogenetic proteins globally. The market overview section of the report comprises qualitative analysis of the overall bone morphogenetic proteins market considering the factors determining the market dynamics such as drivers, restraints and opportunities, along with Porter’s Five Forces analysis and market attractiveness analysis. In addition, various analyses such as event regulatory scenario and value chain analysis have also been provided. Value chain analysis includes the study of major steps involved in the recombinant bone morphogenetic proteins preparation and distribution. Regulatory scenario includes the study of different regulatory norms and procedures that regulate the approval and commercialization of recombinant bone morphogenetic proteins products.
The global bone morphogenetic proteins market has been segmented based on type, application and geography. Based on type, the global BMP market has been categorized into recombinant bone morphogenetic protein-2 (rhBMP-2) and recombinant bone morphogenetic protein-7 (rhBMP-7). Based on application, the bone morphogenetic proteins market has been classified into spinal fusion, trauma, reconstructive and oral maxillofacial surgery. The market for these types and applications has been extensively analyzed on the basis of factors such as product approval date, product demand, sales revenue, geographic presence and product features. The market size and forecast in terms of revenue (USD million) for each of these segments have been provided for the period from 2012 to 2022, considering 2013 and 2014 as the base years. The report also provides the compound annual growth rate (CAGR) for each segment for the forecast period from 2014 to 2022.
Geographically, the BMP market has been classified into four major regions: North America, Europe, Asia-Pacific and Rest of the World (RoW). The market size and forecast for each region have been provided for the period from 2012 to 2022, in terms of types and applications, along with the CAGR (%) for the forecast period from 2014 to 2022.
The bone morphogenetic proteins market report also provides a section on the competitive landscape, wherein the market share analysis of leading players in the global bone morphogenetic proteins market in terms of percentage share in 2013 has been discussed. A list of recommendations has also been included for new entrants as well as existing market players to help them establish a strong presence in the market and increase their market shares. The report concludes with the profiles of major players in the global bone morphogenetic proteins market such as Medtronic plc, Stryker Corporation and Cellumed Co. Ltd. The major market players are evaluated on various parameters such as company overview, financial overview, product portfolio, business strategies and recent developments.
The global bone morphogenetic proteins market is segmented as follows:
Global Bone Morphogenetic Proteins Market Revenue, by Types
Global Bone Morphogenetic Proteins Market Revenue, by Application
- Spinal Fusion
- Reconstructive Surgery
Global Bone Morphogenetic Proteins Market Revenue, by Geography
- North America
- Asia Pacific